The effect of comorbidities on the sFLT-1:PlGF ratio in preeclampsia.

Abstract

Research indicates that soluble fms-like tyrosine kinase 1 (sFLT-1) and placental growth factor (PLGF) have diagnostic and prognostic significance for women with preeclampsia. However, sparse research has studied these biomarkers in women with preexisting comorbidities such as chronic hypertension, diabetes mellitus, systemic lupus erythematosus and chronic kidney disease. We undertook a prospective longitudinal cohort study to compare the sFLT-1: PlGF ratio between women with and without comorbidities who did and did not go on to develop preeclampsia. We found that women with comorbidities may develop preeclampsia with a milder elevation in sFLT-1: PlGF than do women without comorbidities. This has clinical and research implications.

• Authors: Michael S Tanner, Deborah de Guingand, Maya Reddy, Saskia Rowson, Daniel L Rolnik, Mary-Ann Davey, Ben W Mol, Euan M Wallace, Fabricio Da Silva Costa, Kirsten R Palmer
• Journal: Pregnancy hypertension (Pregnancy Hypertens) Vol. 29 Pg. 98-100 (Aug 2022) ISSN: 2210-7797 [Electronic] Netherlands
• PMID: 35843203 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Chemical References

• Biomarkers
• PGF protein, human
• Vascular Endothelial Growth Factor A
• Placenta Growth Factor
• FLT1 protein, human
• Receptor Protein-Tyrosine Kinases
• Vascular Endothelial Growth Factor Receptor-1

Topics

• Biomarkers
• Female
• Humans
• Longitudinal Studies
• Placenta Growth Factor
• Pre-Eclampsia (diagnosis)
• Pregnancy
• Prospective Studies
• Receptor Protein-Tyrosine Kinases
• Vascular Endothelial Growth Factor A
• Vascular Endothelial Growth Factor Receptor-1